See more : Prospect Capital Corporation (PSEC-PA) Income Statement Analysis – Financial Results
Complete financial analysis of Jafron Biomedical Co.,Ltd. (300529.SZ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Jafron Biomedical Co.,Ltd., a leading company in the Medical – Devices industry within the Healthcare sector.
- Wynn Resorts, Limited (0QYK.L) Income Statement Analysis – Financial Results
- OEX S.A. (OEX.WA) Income Statement Analysis – Financial Results
- Shanghai SK Petroleum & Chemical Equipment Corporation Ltd. (002278.SZ) Income Statement Analysis – Financial Results
- TME Pharma N.V. (ALTME.PA) Income Statement Analysis – Financial Results
- Putian Communication Group Limited (1720.HK) Income Statement Analysis – Financial Results
Jafron Biomedical Co.,Ltd. (300529.SZ)
About Jafron Biomedical Co.,Ltd.
Jafron Biomedical Co.,Ltd. engages in the research, development, production, and marketing of biological materials and medical devices in China. It offers solutions for kidney, liver, critical, and rheumatism diseases, as well as poisoning; adsorption products and blood purification machines; and other products, such as single use arteriovenous puncture, hemodialysis online dry powder bags/cylinders, disinfectants, hemodialysis concentrates, and medical adsorbable suture with needles. The company offers its products in Germany, Italy, Turkey, Thailand, Vietnam, the Philippines, South Africa, Kenya, Chile, Peru, and the United Arab Emirates. Jafron Biomedical Co.,Ltd. was founded in 1989 and is based in Zhuhai, China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.92B | 2.49B | 2.68B | 1.95B | 1.43B | 1.02B | 718.49M | 543.64M | 508.91M | 370.94M | 303.59M | 250.62M | 194.98M |
| Cost of Revenue | 383.98M | 440.11M | 402.06M | 287.96M | 197.40M | 154.44M | 113.93M | 87.34M | 78.62M | 56.68M | 49.48M | 43.86M | 34.51M |
| Gross Profit | 1.54B | 2.05B | 2.27B | 1.66B | 1.23B | 862.07M | 604.56M | 456.30M | 430.28M | 314.26M | 254.11M | 206.76M | 160.47M |
| Gross Profit Ratio | 80.03% | 82.34% | 84.97% | 85.24% | 86.21% | 84.81% | 84.14% | 83.93% | 84.55% | 84.72% | 83.70% | 82.50% | 82.30% |
| Research & Development | 245.38M | 253.91M | 173.77M | 80.76M | 68.45M | 46.14M | 26.63M | 21.77M | 17.39M | 15.13M | 9.84M | 12.82M | 0.00 |
| General & Administrative | 48.45M | 32.36M | 31.15M | 25.27M | 28.12M | 22.88M | 16.23M | 16.23M | 13.18M | 9.17M | 6.97M | 32.60M | 25.26M |
| Selling & Marketing | 615.97M | 700.63M | 598.49M | 468.44M | 425.89M | 299.34M | 209.66M | 150.49M | 137.17M | 93.56M | 75.28M | 61.55M | 49.38M |
| SG&A | 664.42M | 732.99M | 629.64M | 493.71M | 454.01M | 322.23M | 225.89M | 166.72M | 150.35M | 102.73M | 82.25M | 94.15M | 74.64M |
| Other Expenses | 0.00 | 59.62M | 87.69M | 74.41M | 73.88M | -3.17M | 8.43M | 8.89M | 7.81M | 17.25M | 6.88M | 7.58M | 4.63M |
| Operating Expenses | 994.54M | 1.05B | 891.09M | 648.88M | 596.34M | 428.04M | 310.22M | 229.09M | 202.46M | 143.65M | 113.51M | 98.56M | 78.11M |
| Cost & Expenses | 1.38B | 1.49B | 1.29B | 936.85M | 793.74M | 582.48M | 424.15M | 316.43M | 281.09M | 200.33M | 162.99M | 142.42M | 112.62M |
| Interest Income | 87.96M | 53.26M | 27.79M | 28.82M | 9.61M | 5.42M | 7.17M | 6.01M | 5.17M | 4.99M | 4.98M | 4.98M | 0.00 |
| Interest Expense | 55.29M | 36.04M | 8.91M | 1.29M | 233.50K | 140.57K | 93.03K | 64.87K | 50.03K | 37.87K | 38.20K | 0.00 | 0.00 |
| Depreciation & Amortization | 112.98M | 82.62M | 58.74M | 38.89M | 30.81M | 22.18M | 16.41M | 16.82M | 9.26M | 3.59M | 2.46M | 2.48M | 1.93M |
| EBITDA | 689.29M | 1.14B | 1.48B | 1.07B | 702.33M | 495.45M | 310.54M | 258.34M | 237.08M | 174.20M | 143.06M | 110.67M | 84.29M |
| EBITDA Ratio | 35.86% | 45.38% | 55.16% | 53.96% | 49.09% | 48.85% | 43.23% | 47.59% | 46.77% | 47.42% | 47.29% | 44.27% | 43.06% |
| Operating Income | 543.82M | 1.03B | 1.42B | 1.05B | 680.33M | 476.31M | 331.71M | 233.77M | 232.04M | 174.04M | 145.10M | 112.93M | 86.24M |
| Operating Income Ratio | 28.29% | 41.32% | 53.00% | 54.05% | 47.52% | 46.86% | 46.17% | 43.00% | 45.60% | 46.92% | 47.79% | 45.06% | 44.23% |
| Total Other Income/Expenses | -22.80M | -12.65M | -10.71M | -22.40M | -9.05M | -3.17M | 45.62M | 8.79M | 7.78M | 22.02M | 6.81M | 12.28M | 4.61M |
| Income Before Tax | 521.02M | 1.02B | 1.41B | 1.03B | 671.28M | 473.14M | 340.14M | 241.46M | 239.82M | 191.11M | 151.91M | 120.48M | 90.85M |
| Income Before Tax Ratio | 27.10% | 40.81% | 52.60% | 52.90% | 46.88% | 46.55% | 47.34% | 44.42% | 47.13% | 51.52% | 50.04% | 48.07% | 46.60% |
| Income Tax Expense | 95.30M | 135.89M | 211.38M | 158.95M | 102.59M | 72.19M | 55.69M | 39.34M | 39.38M | 31.07M | 25.13M | 20.45M | 15.09M |
| Net Income | 436.49M | 889.56M | 1.20B | 875.24M | 570.82M | 401.98M | 284.41M | 202.12M | 200.44M | 160.05M | 126.78M | 100.02M | 75.76M |
| Net Income Ratio | 22.71% | 35.70% | 44.73% | 44.87% | 39.87% | 39.55% | 39.58% | 37.18% | 39.39% | 43.15% | 41.76% | 39.91% | 38.86% |
| EPS | 0.55 | 1.12 | 1.49 | 1.10 | 0.72 | 0.51 | 0.36 | 0.27 | 0.28 | 0.23 | 0.18 | 0.14 | 0.31 |
| EPS Diluted | 0.55 | 1.12 | 1.49 | 1.08 | 0.72 | 0.51 | 0.36 | 0.27 | 0.28 | 0.23 | 0.18 | 0.14 | 0.31 |
| Weighted Avg Shares Out | 793.62M | 797.82M | 803.23M | 795.67M | 791.01M | 787.38M | 783.08M | 738.47M | 705.26M | 707.19M | 708.50M | 703.87M | 248.19M |
| Weighted Avg Shares Out (Dil) | 793.62M | 797.82M | 803.23M | 810.41M | 791.01M | 787.38M | 783.17M | 738.51M | 705.26M | 707.19M | 708.50M | 703.87M | 248.19M |
Source: https://incomestatements.info
Category: Stock Reports